Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05845606
Other study ID # R21DA053394-01A1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 31, 2023
Est. completion date November 30, 2023

Study information

Verified date April 2023
Source University of California, Los Angeles
Contact Kate Taylor-Wolitzky, PhD
Phone 3102069391
Email kbtaylor@mednet.ucla.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to examine the efficacy of a telehealth-delivered cognitive behavioral therapy (CBT) + benzodiazepine taper (BZ-TP) program in facilitating reductions in benzodiazepine use among patients who are prescribed opioids for pain.


Description:

This study will examine the efficacy of adding a cognitive behavioral therapy (CBT) program developed and evaluated for patients with anxiety disorders to a benzodiazepine (BZ) taper as an augmentation strategy to improve the success of benzodiazepine reduction among patients taking concurrent opioid prescriptions for pain. There is a high risk of mortality including fatal overdose among patients taking opioids and BZs, yet it remains a prevalent problem. Treating underlying anxiety contributing to BZ use and potentially implicated in pain has the potential to decrease BZ use and possibly reduce opioid use. Thus, the current study moves the field forward in testing the efficacy of a combined CBT + BZ taper compared to the BZ taper plus a health education control condition. All interventions will be delivered via telehealth to patients recruited from a primary care clinic, where BZ and opioid co-prescribing is common and primary care providers may lack the tools and resources to effectively taper their patients off BZs. Participants who are co-prescribed benzodiazepines and opioids and report elevated anxiety symptoms will be randomized to one of two conditions: (1) BZ taper with telehealth delivered CBT to facilitate taper; (2) BZ taper with health education control. Participants will be assessed on anxiety symptoms, BZ use/dose, opioids use/dose at baseline, post-treatment, and at a 2-month follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date November 30, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Have been taking prescribed BZs for at least 3 months prior to baseline and have a positive UDS for BZs at baseline; - Currently experience significant distress or impairment due to their anxiety symptoms (i.e., score = 8 on the OASIS during screening - Have been prescribed opioids for at least 3 months for pain management and have a positive UDS for prescribed opioids at baseline - Between 18-85 years old - Fluent in English - Have access to a digital device with internet access for telehealth. - Willing to reduce BZ use. Exclusion Criteria: - Pregnancy - Psychiatric symptoms requiring a higher level of care (i.e., severe suicidality, manic or psychotic symptoms not stabilized on medication, presence of any SUD other than tobacco use disorder, OUD (co-occurring with pain condition) or sedative/hypnotic use disorder) - Medical conditions that require ongoing treatment with benzodiazepines (e.g., certain seizure disorders) - Use of drugs other than BZs and opioids in the past 30 days (as indicated by UDS and self-report, with the exception of intermittent cannabis use) - Use of alcohol above at-risk drinking cutoffs per US Dietary Guidelines - Marked cognitive impairment

Study Design


Intervention

Behavioral:
Benzodiazepine Taper
The BZ-TP is a 14-week intervention that assists participants in reducing their benzodiazepine prescription through a gradual taper at approximately 10%-20% reduction per week for a total of 12 weeks. Dose reduction will be recommended but not required. This intervention is identical in both arms.
Cognitive Behavioral Therapy (CBT)
The telehealth delivered CBT is an 11-week intervention that includes psychoeducation, interoceptive exposure, somatic skills, and cognitive restructuring.
Health Education
The Health Education (HE) intervention will include 11 weeks of an interactive health education program to match for therapy time. The HE is a published multimedia program addressing various health, wellness and lifestyle topics such as nutrition, dental care, immunizations, health screening, smoking, and time management.

Locations

Country Name City State
United States UCLA Health MPTF Toluca Lake Primary Care Clinic Burbank California

Sponsors (3)

Lead Sponsor Collaborator
University of California, Los Angeles Boston University, UCLA Health MPTF Toluca Lake Primary Care Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Timeline Followback Assesses for change in benzodiazepine use frequency and dose across study duration Baseline, Weekly for the duration of treatment (up to 20 weeks), post-treatment (at 20 weeks post baseline), and at 2-month follow-up
Primary Depression, Anxiety, & Stress Scale Assesses for change in anxiety symptom severity across study duration Baseline, Weekly for the duration of treatment (up to 20 weeks), post-treatment (at 20 weeks post baseline), and at 2-month follow-up
Secondary Anxiety Sensitivity Index Used to assess for change in anxiety sensitivity across the duration of the study as a secondary outcome and potential treatment mediator Baseline, Bi-weekly for the duration of treatment (up to 20 weeks), post-treatment (at 20 weeks post baseline), and at 2-month follow-up
Secondary Pain Catastrophizing Scale Assesses for change in pain catastrophizing across the duration of the study as a secondary outcome related to opioid use, which will also be examined as a potential mediator of treatment outcome Baseline, Bi-weekly for the duration of treatment (up to 20 weeks), post-treatment (at 20 weeks post baseline), and at 2-month follow-up
Secondary Timeline Followback Assesses changes in opioid use and dose across study duration Baseline, Weekly for the duration of treatment (up to 20 weeks), post-treatment (at 20 weeks post baseline), and at 2-month follow-up
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain